| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1995;60:1755-1761
© 1995 The Society of Thoracic Surgeons
a Department of Cardiac Surgery and Anesthesiology, Oslo Heart Center, Oslo, Norway
b Department of Immunology and Transfusion Medicine, Nordland Central Hospital, Oslo, Norway
c University of Tronsø, Tromsø, Norway
d Surgical Department A and Institute of Surgical Research, The National Hospital, Oslo, Norway
Accepted for publication August 7, 1995.
* Address reprint requests to Dr Øvrum, Oslo Heart Center, Pilestredet 32, 0027 Oslo, Norway.
Background.: Cardiopulmonary bypass with heparin-coated circuits allows reduced amounts of systemic heparin. Heparin inhibits activation of the complement cascade experimentally, but the effects of different levels of systemic heparin on activation of complement and granulocytes in patients have remained unknown.
Methods.: Fifty-two patients undergoing coronary artery bypass procedures were studied. Cardiopulmonary bypass circuits completely coated with surface-bound heparin were used for one group given low-dose heparin (n = 17) (activated clotting time >250 seconds), and was compared with a second group having normal high-dose heparin (activated clotting time >480 seconds) (n = 18). A third control group was perfused with ordinary uncoated circuits and a full heparin dose (n = 17).
Results.: During cardiopulmonary bypass, the C3 activation products C3b, iC3b, and C3c increased markedly in all three groups compared with baseline, but significantly less in the two heparin-coated groups (high dose, median maximal increase 58 arbitrary units (AU)/mL; low dose, 48 AU/mL) compared with the uncoated control group (74 AU/mL) (p < 0.01). The difference between the two coated groups was not significant. Similarly, the maximal increase in terminal SC5b-9 complement complex was considerably lower in the heparin-coated groups (high dose, 2.5 AU/mL; low dose, 2.6 AU/mL) compared with the level observed in the uncoated control group (5.3 AU/mL) (p < 0.01). The release of the granulocyte activation enzymes myeloperoxidase and lactoferrin increased from the beginning of the operation, with peak levels at the end of cardiopulmonary bypass (p < 0.01). The concentration of lactoferrin was significantly (p < 0.01) reduced in the low heparin dose group compared with the two other groups receiving normal high heparin doses, indicating that circulating heparin is an important granulocyte agonist, acting independently of the presence or absence of heparin-coated surfaces. Also for myeloperoxidase a higher level was observed in the high heparin dose group.
Conclusions.: Complement activation was significantly reduced in both heparin-coated groups and was independent of the level of systemic heparinization, whereas granulocyte activation was reduced only in patients who received low doses of systemically administered heparin. The results indicate that a moderate reduction of the systemic heparin dose may be an advantage with regard to improved biocompatibility when using heparin-coated cardiopulmonary bypass circuits.
This article has been cited by other articles:
|
|
 |
|
  J. W. Hammon Extracorporeal Circulation: Perfusion System Card. Surg. Adult, January 1, 2008; 3(2008): 350 - 370. [Full Text]
|
|
|
|
 |
|
 O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes Eur J Cardiothorac Surg, June 1, 2007; 31(6): 1058 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Khoshbin, A. E. Dux, H. Killer, A. W Sosnowski, R. K Firmin, and G. J Peek A comparison of radiographic signs of pulmonary inflammation during ECMO between silicon and poly-methyl pentene oxygenators Perfusion, January 1, 2007; 22(1): 15 - 21. [Abstract] [PDF]
|
|
|
|
|
|
E. Khoshbin, C. Westrope, S. Pooboni, D. Machin, H. Killer, G. J Peek, A. W Sosnowski, and R. K Firmin Performance of polymethyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicone membrane oxygenators Perfusion, May 1, 2005; 20(3): 129 - 134. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Ovrum, G. Tangen, S. Tollofsrud, R. Oystese, M. A. L. Ringdal, and R. Istad Cold blood cardioplegia versus cold crystalloid cardioplegia: A prospective randomized study of 1440 patients undergoing coronary artery bypass grafting J. Thorac. Cardiovasc. Surg., December 1, 2004; 128(6): 860 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Hessel II and L. H. Edmunds Jr. Extracorporeal Circulation: Perfusion Systems Card. Surg. Adult, January 1, 2003; 2(2003): 317 - 338. [Full Text]
|
|
|
|
|
|
M. Johnell, G. Elgue, R. Larsson, A. Larsson, S. Thelin, and A. Siegbahn Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 321 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Aldea, L. O. Soltow, W. L. Chandler, C. M. Triggs, C. R. Vocelka, G. I. Crockett, Y. T. Shin, W. E. Curtis, and E. D. Verrier Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 742 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-C. Hsu Heparin-coated cardiopulmonary bypass circuits: current status Perfusion, September 1, 2001; 16(5): 417 - 428. [Abstract] [PDF]
|
|
|
|
|
|
M. Codispoti and P. S Mankad Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice Perfusion, May 1, 2000; 15(3): 191 - 201. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-O. Defraigne, J. Pincemail, R. Larbuisson, F. Blaffart, and R. Limet Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration Ann. Thorac. Surg., April 1, 2000; 69(4): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Wendel and G. Ziemer Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation Eur J Cardiothorac Surg, September 1, 1999; 16(3): 342 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Mahoney and G. M. Lemole Transfusion after coronary artery bypass surgery: the impact of heparin-bonded circuits Eur J Cardiothorac Surg, August 1, 1999; 16(2): 206 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. McCarthy, J.-P. P. Yared, R. C. Foster, D. A. Ogella, J. A. Borsh, and D. M. Cosgrove III A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations Ann. Thorac. Surg., May 1, 1999; 67(5): 1268 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ranucci, A. Mazzucco, R. Pessotto, G. Grillone, V. Casati, L. Porreca, R. Maugeri, M. Meli, P. Magagna, S. Cirri, et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial Ann. Thorac. Surg., April 1, 1999; 67(4): 994 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Videm, T. E. Mollnes, E. Fosse, B. Mohr, MD, K. Bergh, T.-A. Hagve, A. O. Aasen, and J. L. Svennevig HEPARIN-COATED CARDIOPULMONARY BYPASS EQUIPMENT. I. BIOCOMPATIBILITY MARKERS AND DEVELOPMENT OF COMPLICATIONS IN A HIGH-RISK POPULATION J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 794 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Aldea Heparin-Bonded Circuits Decrease Thromboembolic Complications and Improve Outcomes in Patients Undergoing Coronary Artery Bypass Graft Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 1999; 3(1): 9 - 16. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Hyde, J. A Chinn, and T. R Graham Platelets and cardiopulmonary bypass Perfusion, December 1, 1998; 13(6): 389 - 407. [PDF]
|
|
|
|
|
|
C B. Mahoney Heparin-bonded circuits: clinical outcomes and costs Perfusion, May 1, 1998; 13(3): 192 - 204. [Abstract] [PDF]
|
|
|
|
|
|
O. M. Shapira, G. S. Aldea, P. R. Treanor, R. M. Chartrand, K. M. DeAndrade, H. L. Lazar, and R. J. Shemin Reduction of Allogeneic Blood Transfusions After Open Heart Operations by Lowering Cardiopulmonary Bypass Prime Volume Ann. Thorac. Surg., March 1, 1998; 65(3): 724 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Aldea, P. O'Gara, O. M. Shapira, P. Treanor, A. Osman, E. Patalis, C. Arkin, R. Diamond, V. Babikian, H. L. Lazar, et al. Effect of Anticoagulation Protocol on Outcome in Patients Undergoing CABG With Heparin-Bonded Cardiopulmonary Bypass Circuits Ann. Thorac. Surg., February 1, 1998; 65(2): 425 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ranucci, E. Ovrum, and V. Videm Antithrombin III, Leukocyte Activation, and Low Systemic Heparinization Ann. Thorac. Surg., April 1, 1997; 63(4): 1211 - 1212. [Full Text]
|
|
|
|
|
|
E. Ovrum, E. A. Holen, G. Tangen, and M.-A. L. Ringdal Heparinized Cardiopulmonary Bypass and Full Heparin Dose Marginally Improve Clinical Performance Ann. Thorac. Surg., October 1, 1996; 62(4): 1128 - 1133. [Abstract] [Full Text]
|
|
|
|
|
|
G. S. Aldea, M. Doursounian, P. O'Gara, P. Treanor, O. M. Shapira, H. L. Lazar, and R. J. Shemin Heparin-Bonded Circuits With a Reduced Anticoagulation Protocol in Primary CABG: A Prospective, Randomized Study Ann. Thorac. Surg., August 1, 1996; 62(2): 410 - 418. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ovrum, L. Nilsson, P. Venge, J. W. Borowiec, and S. Thelin Eosinophil Granulocyte Activation and Heparin-Coated Cardiopulmonary Bypass Ann. Thorac. Surg., March 1, 1996; 61(3): 1038 - 1039. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
